AI and Traditional Chinese Medicine Integration - AI is being used to analyze traditional Chinese medicine (TCM) with precision [1] - The integration of AI with TCM combines old wisdom with modern tools [1] - AI is used to analyze components of Chinese herbal medicines, predict drug interactions, and accelerate research and development [6] - A company developed an app using AI to analyze tongue photos for health assessments and personalized wellness tips [7] Traditional Chinese Medicine Principles - TCM focuses on syndrome differentiation and holistic treatment [2] - TCM emphasizes treating the human body as a whole [2] - Acupuncture stimulates acupoints to regulate the body for pain relief and recovery [2] - Traditional methods rely on experience and inheritance [3] Modern Medicine and Technology - Modern medicine uses cutting-edge technology to combat diseases with precision [3] - Pharmaceutical research uses bioengineering, monoclonal antibodies, and gene therapy [3] - Modern medicine uses data and technology to defeat diseases [4] Synergistic Benefits - The combination of traditional inspection methods with AI provides better solutions for patients [8] - The integration extends medical concepts, combining holistic views with precision and efficiency [8] - This collision breaks boundaries and paves new paths for better healthcare [9]

Overview of Traditional Chinese Medicine (TCM) - TCM and Chinese culture have deeply influenced generations, encompassing practices from koji-making to pharmaceutical preparation and philosophical concepts like yin and yang [1] - Dr Wen Junkai advocates integrating traditional Chinese and Western medicine, emphasizing harmony and mutual enjoyment despite differing approaches [1] Dr Wen Junkai's Accomplishments and Affiliations - Dr Wen holds a Ph D in Chinese Medicine and has received multiple awards, including recognition from the China Association of Chinese Medicine [1] - Dr Wen serves as director of the Chinese Medicine Program at the Cross-Straits Fair for Economy and Trade, a columnist for "TCM Insights," and a writer for Shanghai Chinese Medicine Daily [1] - Dr Wen has participated in projects such as the Ministry of Education's Belt and Road International Cooperation and the China-Philippines TCM Center project [1] Joyage and Community Engagement - Dr Wen founded Joyage, a nonprofit dedicated to advancing TCM internationalization and community health promotion [1] - Joyage connects a citywide health ecosystem across 52 universities, community centers, and commercial complexes in Shanghai [1] - Joyage's initiatives, including "TCM in Schools" and "Health Literacy Academy for Seniors," have served over 50,000 people [1]

Healthcare Integration - Singapore will integrate traditional Chinese medicine (TCM) treatments into its public healthcare system [1] - The goal is to explore how TCM therapies can complement Western medicine [1]

Core Viewpoint - Regencell Bioscience Holdings Ltd., a Hong Kong-based biotech startup, has experienced an extraordinary stock price increase of over 59,000% in 2025, reaching a market value of nearly $30 billion despite having no reported revenue [1][3]. Company Overview - Regencell is focused on developing traditional Chinese herbal treatments for childhood ADHD and autism, in collaboration with TCM practitioner Sik-Kee Au, who is also the CEO's father [3]. - The company has not generated any revenue or received regulatory approval for its products, and its latest annual report indicates net losses of $4.36 million and $6.06 million for the fiscal years ending June 2024 and 2023, respectively [3][4]. Stock Performance - Following a 38-for-1 stock split announced in June, Regencell's stock surged by over 280% on a single day [1]. - The company's market valuation is now comparable to major firms like Lululemon Athletica, Inc. and exceeds that of Super Micro Computer, Inc. and Reddit, Inc. [2]. Shareholder Structure - The CEO of Regencell holds 86% of the company's outstanding shares, which may be influencing the stock price dynamics [4]. Market Sentiment - Regencell has become a trending stock on platforms like Yahoo Finance and Stocktwits, with mixed social media commentary. Some retail investors are enthusiastic about the stock's volatility, while others express skepticism, likening its trading behavior to that of meme coins [5]. - As of Tuesday, Regencell shares were up 23% at $73.80 [5].

Core Insights - Regencell's stock has experienced a dramatic increase, with shares rising over 280% in a single day, following a 38-for-1 stock split [2][4] - The company, which focuses on traditional Chinese herb treatments for ADHD and autism, has seen its market capitalization reach approximately $29.7 billion [1][2] - Despite the stock surge, Regencell has not generated any revenue and has incurred significant net losses in recent fiscal years [9][10] Company Overview - Regencell, founded in 2014, is a Hong Kong-based bioscience company that trades on Nasdaq under the ticker 'RGC' since 2021 [1][2] - The CEO, Yat-Gai Au, controls 86.24% of the total shares outstanding [1] - The company develops proprietary Traditional Chinese Medicine (TCM) formulas aimed at treating ADHD and Autism Spectrum Disorders (ASD) [7][8] Financial Performance - Regencell reported total net losses of $4.36 million and $6.06 million for the fiscal years ended June 2024 and 2023, respectively [9] - The company has not generated any revenue from its TCM formula candidates nor applied for regulatory approvals [10] Market Activity - The stock's volatility is notable, with significant one-day price swings, including a 30% increase followed by a 30% decrease on consecutive trading days [6] - Regencell's market value is now comparable to established companies like Lululemon and exceeds that of Super Micro Computer and Fifth Third Bancorp [3] Product Development - Regencell's TCM formula candidates are designed to address varying severities of ADHD and ASD, utilizing natural ingredients [8] - The company has conducted limited efficacy trials, with a recent case study indicating symptom improvement in 28 patients over three months [11] Industry Context - The surge in Regencell's stock coincides with a growing interest in alternative medicines, particularly following the appointment of Robert F. Kennedy Jr. as Secretary of the U.S. Department of Health and Human Services [5] - Regencell's stock has drawn comparisons to other speculative stocks, such as AMTD Digital, which also saw significant price increases without substantial fundamentals [3]

As filed with the U.S. Securities and Exchange Commission on September 13, 2024 Registration No. 333-260183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 21 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) Jupit ...

As filed with the U.S. Securities and Exchange Commission on July 12, 2024 Registration No. 333-260183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 18 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. (State or ...